Drug Profile
Magrolimab - Forty Seven
Alternative Names: 5F9; GS-4721; Hu5F9 G4; Magrolimab - Forty-Seven/Stanford-University; ONO 7913Latest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Forty Seven; Gilead Sciences; M. D. Anderson Cancer Center; Merck KGaA; Merck Sharp & Dohme; National Cancer Institute (USA); Ono Pharmaceutical; Roche; Stanford University; University of California at San Francisco
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
- Phase II Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Head and neck cancer; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours; Triple negative breast cancer
- Phase I Brain cancer; Cutaneous B-cell lymphoma; Lymphoma; Neuroblastoma; Osteosarcoma; Pancreatic cancer
- No development reported Ovarian cancer
Most Recent Events
- 01 Mar 2024 Gilead Sciences suspends a phase II trial for Head and neck cancer (Combination therapy, Late-stage disease, Locally recurrent, Metastatic disease, Second-line therapy or greater) in the USA (IV, Infusion), as per PI request (NCT06046482)
- 27 Feb 2024 Gilead Sciences terminates phase-II ACT-AML-101 trial for Acute myeloid leukaemia (Combination therapy, First-line therapy) in United Kingdom (IV) (ISRCTN71474257)
- 24 Feb 2024 University of California and Gilead Sciences terminates a Phase-I clinical trials in Brain cancer (Metastatic disease, In children, Recurrent) in USA (IV) due to partial clinical hold by FDA (NCT05169944)